Crown Bioscience, Inc. is a platform technology company providing drug discovery and development services in the areas of Oncology and Inflammation.
CrownBio helps biopharmaceutical companies solve some of today's most pressing challenges in oncology with an offering of end-to-end preclinical solutions, a unique collection of ready-to-run, well-validated in vitro, in vivo, and ex vivo models, and cutting-edge technologies.
Our Translational Platforms bring clarity to drug discovery and enable clients around the world to deliver superior clinical candidates.
CrownBio provides preclinical immunotherapy research platforms to support the successful transition of immunotherapeutics from the lab into the clinic including models for the evaluation of CAR-T therapies, syngeneics, and humanized models.
Our team of experts worldwide, comprising highly trained PhD and MS scientists, provides services to Pharmaceutical, Biotechnology companies, and Biomedical Research Institutes around the world.
Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.
Pharmaron is a contract research organization (CRO).
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services
CRO - Contract Research Organization
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
in vitro Biology
in vitro Screening
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
in vitro ADME
in vivo PK
Drug Product Manufacturing
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
Microdosing Phase 0
SEKISUI XenoTech is a contract research organization (CRO) specializing in nonclinical drug metabolism & drug-drug interaction studies.
Over 25 years, we have grown to serve 98% of the top pharma companies (as well as medium, small and virtual pharma, biotechs, research institutions & universities, and more) by assisting them with pharmacokinetics-related safety studies for the drug candidates they are developing, usually before clinical trials. Our leadership and expertise is trusted by industry professionals and academics alike to provide not only superior services and products, but also industry-leading research and new techniques.
There’s a lot of nuance to understanding pharmacokinetic properties of drug candidates. How they enter/exit specific cells, how long they stay, how they get metabolized by enzymes and what metabolites result—all these properties make up the research area called ADME (Absorption, Distribution, Metabolism and Excretion). ADME represents a key area of preclinical investigation to determine whether a drug is going to be dangerous to someone and to make sure it’s in the correct dose and form to produce the therapeutic effect it’s meant to. In vitro and in vivo studies planned with a consultative approach and tailored study design are key to achieving useful, reliable ADME data.
Drug-drug interactions (DDIs) are a preventable cause of adverse drug reactions which kill or hurt 350,000 hospitalized patients per year. DDI potential can be evaluated using in vitro data and is encouraged by regulatory authorities to be appropriately investigated early in a drug’s development. Our clients come to us because we are global experts in predicting potential DDI issues in the lab before they could happen in a clinical trial volunteer. Doing these studies earlier and with a trusted expert not only instills confidence in your data, but saves money and reduces your risk of late-stage failure.
Learn more about who we are & how we help at xenotech.com
Our company is recognized for excellence in providing ISO 9001monoclonal and polyclonal antibodies, antigens, enzymes, and purified proteins to the research and medical diagnostic marketplace. Nearly all of our products are validated for usage in quantitative sandwich immunoassay and qualitative rapid testing.
We offer immunological reagents worldwide for diagnostics & research in the following disciplines:
We are happy to inform you that Advanced ImmunoChemical is now offering a set of antibodies produced In vitro. In addition, some of our current antibodies are now available both as In vivo- and In vitro-produced products.
Monoclonal antibodies and mammalian antigens for detecting infectious diseases, cardiac biomarkers, and hormones.
Broad selection antibodies and inactivated viral antigens to detect Influenza A and B in clinical samples.
Monoclonal antibodies for the detection of biological threats and dangerous pathogens.
Biomarkers for cardiovascular disease prevention, risk assessment, and diagnostics.
Customers Include: Princeton University, Duke University School of Medicine, Columbia University Medical Center, CDC, National Institutes of Health, Naval Health Research Center, Los Alamos National Laboratory, US Army Medical Research Institute of Infectious Diseases, Sandia National Laboratories, Stanfored Medicine, NIST, NIMH, Harvard Medical School, Yale University School of Medicine, John Hopkins School of Medicine, Lawrence Livermore National Laboratory, and many more!
Advanced ImmunoChemical is a WBENC-certified woman-owned small business, since 1986.
AfaSci, Inc., a San Francisco Bay Area biotech company committed to enhancing health care by conducting R&D in both Biotechnology and Therapeutics. Our bioengineering team has designed, produced and been marketing an in vivo drug screening platform, SmartCageTM. This system enables automated, and objective assessment of drug effects on rodent behavior and increases throughput of phenotyping of transgenic animals. Elevating our proprietary platform and well-established electrophysiological techniques, AfaSci’s scientists have been discovering IND drug candidates targeting ion channels and GPCR for the treatment of CNS disorders, especially neuropathic pain, epilepsy and Alzheimer’s disease.